Print

Active Biotech's Novel Cancer Treatment ANYARA Shows Pharmacological Proof of Concept after Successful Phase I Studies

2006-12-13

Active Biotech (ACTI.ST) today announced the successful completion of three clinical Phase I studies of ANYARA for the treatment of advanced non-small cell lung cancer (NSCLC), renal cell cancer (RCC) and pancreatic cancer (PC). These studies confirm that ANYARA has now demonstrated pharmacological proof of concept.
pdfRead the complete press release - December 13, 2006



Back